Andrea van Elsas

Dr. van Elsas is currently supporting Gilde Healthcare as an Operational Partner in the evaluation of investment opportunities. In addition, Dr. van Elsas is VP Research of AM Pharma, a company developing recombinant human Alkaline Phosphatase for inflammatory diseases. He previously served as Chief Scientific Officer of Aduro Biotech, Inc having joined Aduro with the 2015 acquisition of immuno-oncology company BioNovion, a company he co-founded.

He currently serves on the Board of Lava Therapeutics, and on the Scientific Advisory Board of InteRNA Technologies. He holds a Ph.D. in Immunology and Oncology from the University of Leiden.